The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Psychiatry"
DOI: 10.3389/fpsyt.2019.00648
Abstract: There are currently no regulatory approved pharmacological treatments for cognitive impairment associated with schizophrenia (CIAS). One possibility is that trial methodology itself is hindering their development. Emerging evidence suggests that patients with schizophrenia may show… read more here.
Keywords: schizophrenia; pharmacotherapy trials; cognitive impairment; impairment ... See more keywords